TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06206564: Artesunate Ointment for the Treatment of Anal HSIL in HIV-negative Participants

Sponsor: Frantz Viral Therapeutics, LLC · Phase: PHASE2 · Area: INFECTIOUS_VACCINE · Target Enrollment: 48 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$1,617,000

Rescue Site Savings

+$1,058,400

Unlock Full NCT06206564 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06206564 Rescue Dossier →